

March 12, 1965

Vincent Y. Cremata, Jr., M.D.
Associate Director of Clinical Research
Chas. Pfizer & Co., Inc.
Groton, Connecticut

Dear Dr. Cremata:

Thank you very much for sending us the information on your new compound, P-4657B.

In these laboratories, we have come to depend on the EEG changes as one of the more significant indices of psychotropic drug activity. I would be grateful if you would share with us any EEG data that you may have, especially if it was collected in man. If there are behavioral data concurrently, this would make our considerations much more reliable.

Thank you for sending this information to us.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF: jm